These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 26787417

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim.
    Beck JC, Burke MJ, Tolar J.
    Pediatr Blood Cancer; 2010 Mar; 54(3):490-1. PubMed ID: 19908296
    [No Abstract] [Full Text] [Related]

  • 3. Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura.
    Fozza C, Pardini S, Marras T, Longu F, Isoni A, Contini S, Longinotti M.
    Ann Hematol; 2014 May; 93(5):899-900. PubMed ID: 24081576
    [No Abstract] [Full Text] [Related]

  • 4. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J, Katsandris A, Raptis SD, Mantzourani M.
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A.
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract] [Full Text] [Related]

  • 7. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
    Al-Nawakil C, Park S, Chapuis N, Dreyfus F, Szwebel TA, Gibault L, Molina T, Hermine O, Bouscary D, Tamburini J.
    Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.
    Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI.
    Br J Haematol; 2010 May; 149(4):625-8. PubMed ID: 20148887
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Remissions after long-term use of romiplostim for immune thrombocytopenia.
    Marshall AL, Scarpone R, De Greef M, Bird R, Kuter DJ.
    Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
    [No Abstract] [Full Text] [Related]

  • 13. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chronic immune thrombocytopenia in children with romiplostim.
    Chaturvedi S, McCrae KR.
    Lancet; 2016 Jul 02; 388(10039):4-6. PubMed ID: 27103125
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, Seshimo A, Motoji T.
    Br J Haematol; 2012 Sep 02; 158(6):798-800. PubMed ID: 22758388
    [No Abstract] [Full Text] [Related]

  • 17. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 18. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, Belton L, Kreuzbauer G.
    Eur J Haematol; 2017 Feb 02; 98(2):112-120. PubMed ID: 27557853
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
    Mahat U, Talati R, Kodish E.
    Pediatr Blood Cancer; 2019 Jun 02; 66(6):e27706. PubMed ID: 30854752
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.